...
首页> 外文期刊>Journal of Korean medical science. >Safety and Efficacy of Off-label and Unlicensed Medicines in Children
【24h】

Safety and Efficacy of Off-label and Unlicensed Medicines in Children

机译:儿童禁忌和无牌药物的安全性和有效性

获取原文
           

摘要

Background The aim of this study was to explore the use of off-label/unlicensed drugs to confirm the safety and efficacy of their prescription in children in Korea. Methods In this retrospective study, we analyzed data of patients who received any of the 32 drugs between January–December 2014 in tertiary hospitals in Korea, including demographics, diagnoses, reasons for the medication, administration route, and details of adverse drug reactions. Additionally, the mortality in the cohort was assessed. The primary outcomes were efficacy and safety, including mortality, of these drugs in pediatric patients. The secondary outcomes were the current statuses of the use of off-label/unlicensed drugs in two centers. Results Totally, 5,130 prescriptions were found in 2,779 patients. Age (73.5%) and indication (11.7%) were the most frequent reasons for prescriptions being off-labeled/unlicensed. Approximately 88% of the prescriptions were effective, and 19% of the patients developed adverse drug reactions. The number of prescriptions was significantly higher in children with adverse drug reactions than it was in those without (2.8 vs. 1.5; P Conclusion Children are still prescribed medicines that are not authorized in terms of age, weight, indications, or routes of administration. Therefore, many old products require re-assessment of authorization. More prospective clinical studies should be performed to confirm the efficacy and safety of drugs in the pediatric population.
机译:背景技术这项研究的目的是探索在韩国儿童中使用标签外/未许可药物以确认其处方药的安全性和有效性。方法在这项回顾性研究中,我们分析了2014年1月至12月在韩国三级医院接受32种药物治疗的患者的数据,包括人口统计学,诊断,用药原因,给药途径以及药物不良反应的详细信息。另外,评估了该队列中的死亡率。主要结果是这些药物在儿科患者中的疗效和安全性,包括死亡率。次要结果是两个中心使用标签外/无牌药物的当前状态。结果共计2779例患者中有5130张处方。年龄(73.5%)和适应症(11.7%)是处方贴标/无证的最常见原因。大约88%的处方有效,19%的患者出现药物不良反应。有药物不良反应的儿童的处方数量显着高于没有药物不良反应的儿童(2.8 vs. 1.5; P结论)儿童仍然是未获年龄,体重,适应症或给药途径授权的处方药。因此,许多旧产品需要重新评估授权,应进行更多的前瞻性临床研究以确认药物在儿科人群中的有效性和安全性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号